Navigation Links
Lilly Statement on PDUFA Vote by Senate
Date:6/26/2012

INDIANAPOLIS, June 26, 2012 /PRNewswire/ -- Following is a statement from John C. Lechleiter, Ph.D., chairman, president, and chief executive officer of Eli Lilly and Company (NYSE: LLY), regarding today's Senate vote on S.3187 to reauthorize the Prescription Drug User Fee Act (PDUFA):

"The vote to reauthorize PDUFA is a welcome development and represents an important step forward for medical innovation.

"Thanks to broad bipartisan support of Congress, the FDA will continue to have the necessary resources to review potential new treatments. The new law will make the review process more timely, balanced and efficient, including a strengthened framework for evaluating the benefits and risks of new treatments.

"Since its inception in 1992, PDUFA has enabled the FDA to shorten review time from new drug applications by 60 percent. As a result, patients in the U.S. have had speedier access to more than 1,500 new medicines to treat medical conditions such as cancer, diabetes, cardiovascular disease, and neurological disorders.

"PDUFA will keep our nation at the forefront of medical innovation and allow us to continue delivering new medicines that help patients live longer, healthier, and more productive lives. We look forward to the President's signature on this legislation."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo:

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
2. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
3. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
4. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
5. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
6. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
7. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
8. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
9. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
10. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
11. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , BURLINGTON, Mass., Oct. 16 Palomar Medical ... researcher and developer of light-based systems for cosmetic ... with Johnson & Johnson Consumer Companies Inc ("JJCC"), ... test and commercialize home-use, light-based devices for (i) ...
... 16 Reportlinker.com announces that a new market ... Reportlinker Adds Pharma 101: An Overview ... , http://www.reportlinker.com/p0155107/Reportlinker-Adds-Pharma-101-An-Overview-of-the-Life-Sciences-Industry-(Analyst-Insight).html , Introduction , ... Without having the proper background, it can be ...
Cached Medicine Technology:Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 2Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 3Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 4Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 5Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight) 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... several commonly-prescribed dementia drugs may be putting elderly Canadians ... , Cholinesterase inhibitors (Aricept, Exelon and Reminyl) are often ... because they increase the level of a chemical in ... drugs are known to provoke slower heart rates and ...
... Public Welfare Estelle B. Richman today responded to critics ... save taxpayers $146 million annually while preserving consumer benefits ... from the Smart Pharmacy initiative are real, not speculative," ... is facing a budget shortfall now and the savings ...
... pain condition common in people with migraines also ... headache, according to a study conducted by researchers ... for Neuroscience. , Approximately half of a group ... a condition that causes patients to have pain ...
... 27 UNICEF has appealed for an additional ... fighting in northwest Pakistan. Over half of the displaced are ... of supplies and funding. , , Humanitarian ... the number of people fleeing fighting that has taken place ...
... of Tennessee and Daiichi Sankyo ATLANTA, ... headquartered in Atlanta, has recently been awarded business ... BlueShield of Tennessee and Daiichi Sankyo, Inc.Studiocom,s healthcare ... these new clients meeting the challenges of the ...
... DIEGO, May 27 ResMed Inc. (NYSE: RMD ... upcoming conferences. David Pendarvis, SVP Organization Development and General Counsel ... the Four Seasons in Chicago on June 10, 2009 at ... CEO will present at the Jefferies Third Annual Healthcare Conference ...
Cached Medicine News:Health News:Dementia drugs may put some patients at risk, Queen's study shows 2Health News:Secretary of Public Welfare Corrects the Record on 'Smart Pharmacy' Initiative 2Health News:UNICEF Appeals for Funding to Urgently Assist Displaced Children and Women in Northwest Pakistan 2Health News:Studiocom Continues Growth with Healthcare Industry Wins 2Health News:Studiocom Continues Growth with Healthcare Industry Wins 3
... SuperAnchors are titanium alloy implants ... to bone. They are indicated ... required. The SuperAnchor uses four ... while maintaining small size. The ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... protection' -- providing complete protection from initial ... with side branches. , ,Proxis is ... not require the attachment or exchange of ... ,Proxis is compatible with all standard ...
... electrophysiology system on the market today, the ... patented "C inside a C" design offering ... ultimate in patient access and flexibility. Usable ... minimizes equipment footprint and can be parked ...
Medicine Products: